Search clinical trials for: vinorelbine

Total 481 results

Shanghai Escugen Biotechnology Co., Ltd

Not yet recruiting

A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Metastatic Breast Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Triple-Negative Breast Cancer

China
Memorial Sloan Kettering Cancer Center
Seagen Inc.

Recruiting

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Hodgkin Lymphoma

United States
Fudan University

Not yet recruiting

Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer

Triple-negative Breast Cancer
Fudan University

Not yet recruiting

Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

Triple-negative Breast Cancer
Jemincare

Not yet recruiting

Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects

Solid Tumor, Adult
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer

HR+HER2- Breast Cancer

China
Guangzhou Institute of Respiratory Disease

Recruiting

Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 Inhibitor

Non-small Cell Lung Cancer Stage IIIB/IV

China
Sun Yat-sen University

Recruiting

Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer

Breast Cancer | Refractory Breast Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Breast Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer

Breast Cancer | Triple Negative Breast Cancer
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Chi-GVM Regimen for the Treatment of R/R PTCL

Relapsed/Refractory Peripheral T-cell Lymphoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

Metastatic Breast Cancer | Advanced Malignancies | Recurrent Breast Cancer

China
Henan Cancer Hospital

Not yet recruiting

Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial

Advanced Breast Cancer | Treatment | HR Low/HER2 Negative
Shanghai Yizhong Pharmaceutical Co., Ltd.

Recruiting

Paclitaxel Polymeric Micelles for Injection Versus TPC on the Treatment of HER2-negative Metastatic Breast Cancer (MBC).

Metastatic Breast Cancer (MBC)

China
Merck Sharp & Dohme LLC

Recruiting

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Israel, Taiwan, United Kingdom, Chile, Canada, Japan, Brazil
Guangdong Provincial People's Hospital
Sun Yat-sen University; First Affiliated Hospital, Sun Yat-Sen University; Shantou...

Recruiting

Organoid-based Functional Precision Therapy for Advanced Breast Cancer (ORIENTA)

Advanced Breast Cancer | HER2-negative Breast Cancer

China
Sichuan Kelun Pharmaceutical Research Institute...

Not yet recruiting

A Phase III Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

Metastatic Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Not yet recruiting

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Breast Cancer

China
St. Jude Children's Research Hospital

Recruiting

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

Rhabdomyosarcoma

United States
Yan Xue

Recruiting

Efficacy and Safety of Metronomic Oral Vinorelbine Plus Anlotinib in HER2-negative Metastatic Breast Cancer Patients

Breast Cancer

China
Eli Lilly and Company

Recruiting

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer (CAMPFIRE)

Adolescent | Neoplasms | Child

United States, Spain, United Kingdom, Australia, Italy, Japan, Belgium, France, Germany
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

DP303c in Patients With HER2-positive Advanced Breast Cancer

HER2-positive Advanced Breast Cancer
Zhejiang Cancer Hospital

Recruiting

Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC (HER2-VIP)

HER2-positive Advanced Breast Cancer

China
University of Miami

Recruiting

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Breast Cancer | Metastatic Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer

United States
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer

Breast Cancer

China
Fudan University

Recruiting

Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer (BCTOP-T-M01)

Triple-Negative Breast Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer

Breast Neoplasms

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer

Breast Cancer

China
Fujian Cancer Hospital

Not yet recruiting

Almonertinib Plus Metronomic Oral Vinorelbine

NSCLC | EGFR | Third-generation TKI
National Research Center for Hematology, Russia

Recruiting

Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma

Hodgkin Lymphoma

Russian Federation
Sichuan Academy of Medical Sciences
Sichuan Provincial People's Hospital

Recruiting

Direct Endovascular Treatment Versus Bridging Treatment In Basilar Artery Occlusive Stroke (BEST-BAO)

Thrombosis | Acute Ischemic Stroke | Basilar Artery Occlusion | Endovascular Treatment | Alteplase

China
Second Affiliated Hospital of Soochow University

Not yet recruiting

Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)

Carcinoma, Non-Small-Cell Lung | Carcinoma Breast

China
Spanish Breast Cancer Research Group
Seagen Inc.

Recruiting

Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer (TrasTUCAN)

HER2-positive Metastatic Breast Cancer | Locally Advanced HER2 Positive Breast Carcinoma

Spain
Qilu Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.

Carcinoma, Non-Small-Cell Lung
Fondazione Italiana Linfomi - ETS
Roche Pharma AG

Recruiting

Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients (FIL_A-BEGEV)

Relapsed or Refractory Hodgkin's Lymphoma

Italy
Henan Cancer Hospital

Recruiting

Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer

Breast Cancer

China
Zhejiang Cancer Hospital
Proswell Medical Corporation

Recruiting

Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC

Metastatic Breast Cancer

China
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

Alveolar Rhabdomyosarcoma | Embryonal Rhabdomyosarcoma | Botryoid-Type Embryonal Rhabdomyosarcoma | Spindle Cell Rhabdomyosarcoma | Spindle Cell/Sclerosing Rhabdomyosarcoma | Metastatic Embryonal Rhabdomyosarcoma | Metastatic Rhabdomyosarcoma | Solid Alveolar Rhabdomyosarcoma

United States, Canada, Australia, Puerto Rico, Saudi Arabia
Zhiyong Yu

Not yet recruiting

Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

Metastatic Breast Cancer
Affiliated Cancer Hospital & Institute of Guangzhou...

Recruiting

Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer

Advanced Non-Small Cell Lung Cancer

China
Fudan University

Not yet recruiting

Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)

Breast Cancer
Children's Cancer Group, China
Qilu Hospital of Shandong University; Shanghai Children's Medical Center; West... and other collaborators

Recruiting

CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL

Pediatric Anaplastic Large Cell Lymphoma

China
Peking University First Hospital

Recruiting

Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy

Neoadjuvant Therapy | Cisplatin | Immunotherapy | HER2-negative Breast Cancer | Pathological Complete Response | Vinorelbine

China
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)

Non Small Cell Lung Cancer
SOLTI Breast Cancer Research Group
Roche Pharma AG

Recruiting

Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer (ATREZZO)

Breast Cancer

Spain
Fudan University

Recruiting

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Triple Negative Breast Cancer

China
Seagen Inc.
Genmab

Recruiting

Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (innovaTV 301)

Cervical Cancer

United States, Canada, Japan, Austria, Belgium, China, France, Korea, Republic of, Netherlands, Singapore, Spain, United Kingdom, Argentina, Brazil, Germany, Italy, Norway, Peru, Poland, Finland, Denmark, Ireland, Czechia, Hungary, Taiwan, Swed... and more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer

Breast Cancer

China
Zhejiang Cancer Hospital

Not yet recruiting

Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer

Breast Cancer

3

Subscribe